59702-21-5

Basic information

• Product Name: 1-BENZYLPIPERAZINE-2-ONE
• Synonyms: 1-BENZYLPIPERAZINE-2-ONE;1-BENZYL-PIPERAZIN-2-ONE;1-Benzylpiperazine-2-one HCl;1-Benzylpiperazine-2-one hydrochloride;1-benzyl-2-piperazinone(SALTDATA: HCl);1-Benzyl-2-oxopiperazine;1-(Phenylmethyl)-2-piperazinone;1-Benzyl-2-piperazinone
• CAS NO: 59702-21-5
• Molecular Formula: C₁₁H₁₄N₂O
• Molecular Weight: 190.24
• Product Categories: pharmacetical
• Mol File: 59702-21-5.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 380.4 °C at 760 mmHg
• Flash Point: 183.9 °C
• Appearance: /
• Density: 1.130
• Vapor Pressure: 5.47E-06mmHg at 25°C
• Refractive Index: 1.562
• PKA: 7.67±0.20(Predicted)
• CAS DataBase Reference: 1-BENZYLPIPERAZINE-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYLPIPERAZINE-2-ONE(59702-21-5)
• EPA Substance Registry System: 1-BENZYLPIPERAZINE-2-ONE(59702-21-5)

Safety Data

• Hazardous Substances Data: 59702-21-5(Hazardous Substances Data)

Usage

Uses

1-Benzylpiperazin-2-one

InChI:InChI=1/C11H14N2O/c14-11-8-12-6-7-13(11)9-10-4-2-1-3-5-10/h1-5,12H,6-9H2

Upstream product

• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 78551-60-7 1-benzyl-4-(tert-butyloxycarbonyl)piperazin-2-one 
• 79179-76-3 1-acetyl-4-benzyl-3-oxopiperazine 

Downstream Products

• 1181802-34-5 1-benzyl-4-(1-triisopropylsilanyl-1H-indazol-5-yl)-piperazin-2-one 
• 1284243-24-8 4-{[3-chloro-6-(1H-pyrazol-4-yl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]carbonyl}-1-(phenylmethyl)-2-piperazinone 
• 1284243-27-1 4-{[3-chloro-6-(3-furanyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl]carbonyl}-1-(phenylmethyl)-2-piperazinone 
• 190953-80-1 1-(phenylmethyl)piperazine-2-thione 
• 1095639-11-4 1-benzyl-4-(4-chlorophthalazin-1-yl)piperazin-2-one 
• 79179-76-3 1-acetyl-4-benzyl-3-oxopiperazine 
• 1016538-48-9 C₁₄H₁₈N₂O₂ 
• 78551-60-7 1-benzyl-4-(tert-butyloxycarbonyl)piperazin-2-one 
• 63784-13-4 N-(2-Benzylaminoethyl)glycine Dihydrochloride 
• 888973-21-5 (2S)-2-[4-chloro-2-[[3-oxo-4-(phenylmethyl)-1-piperazinyl]methyl]phenoxy]-propanoic acid, methyl ester 
• 897934-43-9 C₁₅H₁₈N₄OS 
• 79179-74-1 1-(4-aminobenzyl)-4-benzyl-3-oxopiperazine 
• 79179-73-0 1-benzyl-4-<4-(5-nitro-2-pyridyl)aminobenzyl>-2-oxopiperazine 
• 79179-77-4 1-<4-(5-amino-2-pyridyl)aminobenzyl>-4-benzyl-3-oxopiperazine 

Relevant articles and documents

Histamine H3 receptor antagonists with peptidomimetic (keto)piperazine structures to inhibit Aβ oligomerisation

Alzheime?s disease (AD) is the most prominent neurodegenerative disorder with high medical need. Protein-protein-interactions (PPI) interactions have a critical role in AD where β-amyloid structures (Aβ) build toxic oligomers. Design of disease modifying multi target directed ligand (MTDL) has been performed, which disable PPI on the one hand and on the other hand, act as procognitive antagonists at the histamine H3 receptor (H3R). The synthetized compounds are structurally based on peptidomimetic amino acid-like structures mainly as keto, diketo-, or acyl variations of a piperazine moiety connected to an H3R pharmacophore. Most of them showed low nanomolar affinities at H3R and some with promising affinity to Aβ-monomers. The structure–activity relationships (SAR) described offer new possibilities for MTDL with an optimized profile combining symptomatic and potential causal therapeutic approaches in AD.

Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

A series of β-amino amide containing substituted piperazine-2-one derivatives was synthesized and evaluated as inhibitors of dipeptidyl pepdidase-4 (DPP-4) for the treatment of type 2 diabetes. As results of intensive SAR study of the series, (R)-4-[(R)-3-amino-4-(2,4,5-trifluorophenyl)- butanoyl]-3-(t-butoxymethyl)-piperazin-2-one (DA-1229) displayed potent DPP-4 inhibition pattern in several animal models, was selected for clinical development.

Design, synthesis and preliminary pharmacological evaluation of new piperidine and piperazine derivatives as cognition-enhancers

A series of 2-oxopiperazine, 4-aminomethyl-, 3-amino- and 3-aminomethylpiperidine analogues of DM235 (sunifiram) and MN19 (sapunifiram), two previously reported potent cognition-enhancers, have been synthesized and tested in the mouse passive-avoidance test. The compounds display minimal effective doses in the range 0.3-10 mg/kg. Although the new substances do not show improved activity when compared to the parent compounds, some useful information has been obtained to understand structure-activity relationships. In addition, the 3-aminopiperidine moiety appears to be a promising scaffold to synthesize new drugs endowed with cognition-enhancing activity.